TRIB Stock: Trinity Biotech plc Stock Price, Analysis & Insights
Get live trib stock price $1.02, comprehensive Trinity Biotech plc stock analysis, charts, news, and expert forecast. Real-time trib stock data and investment insights.
Loading chart...
Company Overview
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Company Information
- CEO
- John Gillard
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 380
Contact Information
- Address
- IDA Business Park
- Country
- IE
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Lower volatility stock (Beta: 0.50) may provide portfolio stability
Business Model & Strategy
Trinity Biotech plc operates in the Medical - Diagnostics & Research industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO John Gillard, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Medical - Diagnostics & Research model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Trinity Biotech plc competes in the Medical - Diagnostics & Research within the broader Healthcare. With 10.6 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, Trinity Biotech plc provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Trinity Biotech plc should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Trinity Biotech plc shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Trinity Biotech plc
- ⚠Investors should consider how Trinity Biotech plc fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
10.59M
P/E Ratio
-0.57
Beta
0.50
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 10.59M market capitalization
- Trading Volume: 5.71M shares traded today
- Price Range: 52-week range of $0.48 - $3.44
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Trinity Biotech plc
Trinity Biotech plc (TRIB) operates in the Medical - Diagnostics & Research industry within the Healthcare sector. With a current market capitalization of 10.59M, the company represents a significant player in its market. The stock is currently trading at $1.02 with a negativedaily change of 20.31%.
The company's 380 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -0.57, beta of 0.50, and 52-week price range from $0.48 to $3.44when evaluating investment opportunities.
Why Invest in Trinity Biotech plc?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under John Gillard
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.